Sign In

Sam Quigley

On a mission to cure Dup15q

Sam Quigley is a board member of the Dup15q Alliance, an organization dedicated to supporting individuals and families affected by Dup15q syndrome. He is also the founder and CEO of Kicho Inc., a company focused on developing a novel antisense oligonucleotide (ASO) therapy for Dup15q syndrome, inspired by his son Eamonn, who has the condition. Quigley previously worked as one of the early developers of Square, where he was the first information security hire, and has also contributed to other ventures such as Emerose Advisory Services.123

Quigley's work with Kicho Inc. and his involvement in the Dup15q Alliance reflect his commitment to advancing research and therapeutic solutions for rare genetic disorders like Dup15q syndrome. He collaborates with organizations such as Charles River Laboratories to develop targeted ASO therapies aimed at reducing symptoms of the disorder.13

Highlights

Jul 16 · criver.com
An ASO for Eamonn | Eureka blog - Charles River Laboratories
An ASO for Eamonn | Eureka blog - Charles River Laboratories

Related Questions

What inspired Sam Quigley to start Kicho Inc?
How has Eamonn's condition evolved since the ASO treatment began?
What are the main challenges in developing ASO therapies for rare genetic diseases?
How does the Dup15q Alliance support families dealing with this syndrome?
What role does Charles River Laboratories play in the development of Eamonn's ASO?
Sam Quigley
Sam Quigley, photo 1
Sam Quigley, photo 2
Add to my network

Location

New York, New York, United States